John de Koning, PhD, joined LSP in 2006. He became a Partner of the firm in 2009. His prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, John was the Managing Director of Semaia Pharmaceuticals, a company targeting the development of innovative drugs for various types of cancers and for diabetes. Previously, he was a senior researcher within several prestigious medical research labs and worked among others with Prof Hans Clevers, Prof Hans Bos and Prof Bob Löwenberg. With his unique background combining scientific excellence, business and management experience, John is well equipped to identify and optimize the relevant investment opportunities for the firm. He has been involved in a large number of LSP’s investments and has been appointed a Director in many of these companies. Among others, John is currently a Director at arGEN-X, a Dutch/Belgian company that develops innovative cancer drugs. He is also the organizer of BioCapital Europe, which is regarded as Europe’s premier annual life sciences investment conference. John has a Master’s degree in Medical Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University Rotterdam. After obtaining his PhD, John received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics. John lives in Baarn with his wife and two children.
To contact John directly, email email@example.com or call +31 (0) 20 664 55 00.